Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.

doi:10.1016/j.jhep.2010.07.037

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.

Journal of hepatology - 1 Mar 2011

Kurosaki Masayuki, Tanaka Yasuhito, Nishida Nao, Sakamoto Naoya, Enomoto Nobuyuki, Honda Masao, Sugiyama Masaya, Matsuura Kentaro, Sugauchi Fuminaka, Asahina Yasuhiro, Nakagawa Mina, Watanabe Mamoru, Sakamoto Minoru, Maekawa Shinya, Sakai Akito, Kaneko Shuichi, Ito Kiyoaki, Masaki Naohiko, Tokunaga Katsushi, Izumi Namiki, Mizokami Masashi

Abstract excerpt

BACKGROUND & AIMS: Pegylated interferon and ribavirin (PEG-IFN/RBV) therapy for chronic hepatitis C virus (HCV) genotype 1 infection is effective in 50% of patients. Recent studies revealed an association between the IL28B genotype and treatment response. We aimed to develop a model for the pre-treatment prediction of response using host and viral factors. METHODS: Data were collected from 496 patients with HCV...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Data Mining

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Decision Trees

Share to Genes, Viral

Share to Interferon Type I

Share to Interferons

Share to Interleukins

Share to Ribavirin

Share to Viral Core Proteins

Source

Open in PubMed

Identifiers

PMID: 21129805
DOI: 10.1016/j.jhep.2010.07.037

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.PMID 21129805Read ↗

Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.Semantic proximity Read ↗

Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.Semantic proximity Read ↗

Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C.Semantic proximity Read ↗

Baseline factors associated with treatment response in patients infected with hepatitis C virus 1b by stratification of IL28B polymorphisms.Semantic proximity Read ↗

Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis.Semantic proximity Read ↗

Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype.Semantic proximity Read ↗

Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection.Semantic proximity Read ↗

IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma.Semantic proximity Read ↗

Role of hepatitis C virus substitutions and interleukin-28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy.Semantic proximity Read ↗

Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.Semantic proximity Read ↗

Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b.Semantic proximity Read ↗

Association of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.